FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 3, 2025--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer.
The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide for more effective treatment or diagnosis of life-threatening diseases, such as cancer, than current options. The goal of the FDA's Breakthrough Devices Program is to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment and review.
'Every late-stage cancer we avert is a win for patients and for the entire healthcare system,' said AmirAli Talasaz, Guardant Health co-founder and co-CEO. 'This recognition by the FDA shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw. We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly.'
The Breakthrough Device designation by the FDA of the Shield MCD test builds on its recent selection by the National Cancer Institute (NCI) for the Vanguard Study evaluating emerging MCD technology. The Shield MCD test was chosen for the Vanguard study based on its strong performance in predicting the presence of cancers and cancer tissue of origin.
At the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Guardant presented data on the clinical validation of the Shield MCD test showing that the blood-based test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy across multiple tumor types. The data presented from a case-control cohort showed that the Shield MCD test has 98.6% specificity and 75% cancer sensitivity across bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancers (per-cancer sensitivity range: 62-96%). Primary or secondary CSO (cancer signal origin) accuracy was 92%.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250603684215/en/
CONTACT: Investor Contact:
Zarak Khurshid
[email protected] Contact:
Meaghan Smith
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: FDA HEALTH ONCOLOGY MEDICAL DEVICES
SOURCE: Guardant Health, Inc.
Copyright Business Wire 2025.
PUB: 06/03/2025 08:05 AM/DISC: 06/03/2025 08:03 AM
http://www.businesswire.com/news/home/20250603684215/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Why AI Stock Broadcom Topped the Market on Tuesday
It announced that it started shipping its latest AI chip. The chip is a vast improvement over its predecessor, the company said. Meanwhile, two analysts published bullish updates on the stock. These 10 stocks could mint the next wave of millionaires › A new product rollout is always an attention-grabbing piece of news in the corporate world, and that goes double for businesses involved with artificial intelligence (AI). On Tuesday, specialty chip maker Broadcom (NASDAQ: AVGO) announced it began shipping an advanced networking chip. Investors greeted this by pushing the company's stock up by more than 3% that trading session. That gain easily trounced the 0.6% increase of the S&P 500 index. Broadcom's Tomahawk 6 switch series is now on its way to the market, the company announced that morning (a switch, also known as a switching chip, is a highly specialized component that handles data trafficking through a computer network). According to Broadcom, the Tomahawk 6 boasts double the bandwidth of any switch available on the market just now. It's designed to handle the comparably much higher resource needs of artificial intelligence (AI) functionalities. The company said its new product has an unrivaled set of AI routing features and interconnect options. The announcement came two days before Broadcom is slated to publish its fiscal second quarter of 2025 earnings. What also helped the stock rise was a pair of bullish new analyst notes released in anticipation of those results. Both Citigroup's Christopher Danley and JPMorgan Chase's Harlan Sur maintained their equivalent of buy recommendations in their respective updates. Danley went as far as to raise his price target on the stock significantly to $276 per share from his previous $210. According to reports, Danley believes Broadcom will top analyst estimates for the quarter, especially considering that AI is an important driver of its sales, and demand for the technology remains scorching. I'd be as bullish as those two gentlemen; Broadcom is very well placed to be a main supplier expanding AI capabilities, and its fundamentals should reflect that going forward. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $356,261!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,291!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $657,385!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 2, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Citigroup is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Why AI Stock Broadcom Topped the Market on Tuesday was originally published by The Motley Fool
Yahoo
27 minutes ago
- Yahoo
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): 'It Doesn't Make Any Money'
We recently published a list of . In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other stocks that Jim Cramer discusses. When a caller inquired about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Cramer said: 'You know, look, it doesn't make any money. I've been waiting for it to do something, break out. I just don't know if it has the horses.' A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab. Arrowhead Pharmaceuticals (NASDAQ:ARWR) develops RNA-based treatments for a wide range of hard-to-treat diseases, with multiple drug candidates in clinical trials targeting conditions such as cardiovascular disorders, liver disease, pulmonary illness, and rare genetic disorders. Additionally, in 2019, Cramer said the following about the company: 'I looked at Arrowhead recently and I didn't see that much. You know, everyone's so excited about it. I don't get that. I have been saying that it's absolutely O.K. to own stocks that have to do with slicing and dicing and genes, but I'm not gonna endorse it for anything other than speculation.' For context, since the above comment was aired, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock declined more than 75%. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Forbes
27 minutes ago
- Forbes
FDA's New AI Tool Cuts Review Time From 3 Days To 6 Minutes
AI at the FDA getty The U.S. Food and Drug Administration announced this week that it deployed a generative AI tool called ELSA (Evidence-based Learning System Assistant), across its organization. After a low-profile pilot that delivered measurable gains, the system is now in use by staff across the agency, several weeks ahead of its original schedule. Dr. Marty Makary, the FDA's commissioner, shared a major outcome. A review task that once took two or three days now takes six minutes. 'Today, we met our goal ahead of schedule and under budget,' said Makary. 'What took one scientific reviewer two to three days [before] The FDA has thousands of reviewers, analysts, and inspectors who deal with massive volumes of unstructured data such as clinical trial documents, safety reports, inspection records. Automating any meaningful portion of that stack creates outsized returns. ELSA helps FDA teams speed up several essential tasks. Staff are already using it to summarize adverse event data for safety assessments, compare drug labels, generate basic code for nonclinical database setup, and identify priority sites for inspections, among other tasks. This last item, using data to rank where inspectors should go, could have a real-world impact on how the FDA oversees the drug and food supply chain and impacts on how the FDA delivers its services. Importantly, however, the tool isn't making autonomous decisions without a human in the loop. The system prepares information so that experts can decide faster. It cuts through the routine, not the judgment. One of the biggest questions about AI systems in the public sector revolves around the use of data and third party AI systems. Makary addressed this directly by saying that 'All information stays within the agency. The AI models are not being trained on data submitted by the industry.' That's a sharp contrast to the AI approaches being taken in the private sector, where many large language models have faced criticism over training on proprietary or user-submitted content. In the enterprise world, this has created mounting demand for "air-gapped" AI solutions that keep data locked inside the company. That makes the FDA's model different from many corporate tools, which often rely on open or external data sources. The agency isn't building a public-facing product. It's building a controlled internal system, one that helps it do its job better. Federal departments have been slow to move past AI experimentation. The Department of Veterans Affairs has started testing predictive tools to manage appointments. The SEC has explored market surveillance AI for years. But few have pushed into full and widespread production. The federal government has thousands of employees processing huge volumes of information, most of it unstructured sitting in documents, files, and even paper. That means AI is being focused most on operational and process-oriented activities. It's shaping up to be a key piece of how agencies process data, make recommendations, and act. Makary put it simply that ELSA is just the beginning for AI adoption within the FDA. 'Today's rollout of ELSA will be the first of many initiatives to come,' he said. 'This is how we'll better serve the American people.'
